SGLT2 Inhibitor related polycythaemia: a potential severe side effect.

21 May 2023 (09:18 - 09:27)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Mr Martijn Tukker

Rotterdam (Netherlands (The))

4 More presentations in this session

Presentation thumbnail

Patent ductus arteriosus: an unexpected diagnosis at the adulthood

Doctor F. Duarte (Ponta Delgada, PT)

Presentation thumbnail

Cardiotoxicity? Systematic sclerosis? in quest of answers.

Doctor P. Kourkoveli (Maroussi-Athens, GR)

Presentation thumbnail

Monitoring of volume status using a novel sensor for the assessment of inferior vena cava area and collapsibility in a patient with HFrEF receiving advanced heart failure therapy a case study.

Professor F. Malek (Prague, CZ)

Presentation thumbnail

Measuring the Acute Effects of Cardiac Contractility Modulation (CCM) Therapy with a Non-Invasive Bioimpedance Hemodynamic System (NICaS)

Doctor A. Madeo (Castrovillari, IT)

Access the full session

Session thumbnail

Chronic heart failure 1

The Event

Event poster

Heart Failure 2023

21 May 2023 09:18 CET

You may be interested in

Congress Presentation

Secondary erythrocytosis / polycythemia due to sodium glucose co-transporter 2 inhibitors: a real world heart failure cohort.

Congress Presentation

Uncoupling erythropoiesis from cardiorenal effects: SGLT2 inhibition in non-diabetic heart failure

Congress Presentation

Effects of SGLT-2 inhibitors on erythropoiesis and the associated cardio-renal benefits in patients with chronic heart failure

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources